Vimarsana
Biggest News Aggregation in the World

Page 43 - Heca News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Heca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Heca Today - Breaking & Trending Today

Court denies Elizabeth Holmes' request to remain free while appealing conviction - Vimarsana News

Court denies Elizabeth Holmes' request to remain free while appealing conviction

Theranos founder Elizabeth Holmes and former CEO Ramesh "Sunny" Balwani were on Tuesday ordered to pay $452 million to victims of the blood-testing startup's fraud, and an appeals court also denied Holmes' request to remain out of prison while challenging her conviction.

AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial - Vimarsana News

AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial

The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday.

Factbox: The judges who will decide the appeal over the abortion pill - Vimarsana News

Factbox: The judges who will decide the appeal over the abortion pill

All three of the judges on the 5th U.S. Circuit Court of Appeals panel that will hear the Biden administration's appeal to keep the abortion pill mifepristone on the market are staunchly conservative, with a record of opposing abortion rights. Here is a look at their records.

Cabinet approves MoU between CCI, Egyptian agency for cooperation in competition law, policy - Vimarsana News

Cabinet approves MoU between CCI, Egyptian agency for cooperation in competition law, policy

The MoU reflects the importance of international cooperation in addressing cross-border competition issues and promoting healthy competition in the global marketplace.

US FDA staff flag 'serious' safety risks for Intercept's NASH treatment - Vimarsana News

US FDA staff flag 'serious' safety risks for Intercept's NASH treatment

The U.S. health regulator's staff reviewers on Wednesday raised a string of concerns with Intercept Pharmaceuticals' treatment for a type of fatty liver disease, sending the drugmaker's shares plunging 22%.